An interventional study of multimodal analgesia via dual-chamber PCA and single regimen (only fentanyl) in Morbid Obesity, PCA and Analgesia, sponsored by Seoul National University Bundang Hospital. Recruiting at 1 site in South Korea. Open to female participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-03.
Sponsored by Seoul National University Bundang Hospital · Not applicable, Interventional, and Prevention
Postoperative nausea and vomiting (PONV) are the most common complications that can occur after general anesthesia. Postoperative use of opioids and morbid obesity have been reported as risk factors of PONV. In this study, the investigators aimed to compare the degree of postoperative side effects and pain control when an intravenous patient-controlled analgesia combining fentanyl and ketorolac via a dual-chamber device was provided to participants undergoing laparoscopic sleeve gastrectomy.
Morbidly obese patients undergoing laparoscopic sleeve gastrectomy experience a relatively high incidence of postoperative nausea and vomiting, but no effective treatment method has been established yet to prevent them. Through this study, the investigators can expect that if a dual-chamber patient-controlled analgesia device can provide effective analgesia while reducing the amount of opioid used, and thus reduce postoperative nausea and vomiting, it can have the effect of increasing the quality of recovery and satisfaction of participants who have undergone laparoscopic sleeve gastrectomy. Furthermore, this dual-chamber patient-controlled analgesia device can be applied to various surgeries and various patient groups who are at risk for postoperative nausea and vomiting, and it is expected that it can be adapted as one of the methods to prevent postoperative nausea and vomiting.
922 studies on the registry are indexed under Obesity, Morbid; 172 are open to participants now.
This study's planned enrollment of 92 is above the median of 60 across 590 interventional studies indexed under Obesity, Morbid.
Browse Obesity, Morbid studies →Seoul National University Bundang Hospital is the lead sponsor of 368 studies on the registry; 55 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Device: multimodal analgesia via dual-chamber PCA
Device: single regimen (only fentanyl)
combination of fentanyl and ketorolac through dual-chamber PCA
fentanyl only through dual-chamber PCA
postoperative nausea and vomitting
The Quality of Recovery score 15
Time frame: postoperative 1 day
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Bundang Hospital